



With the support of



THE 2nd GCC RHEUMATOLOGY CONFERENCE

PROGRAM

February 3-5, 2022 | Virtual Meeting

14 CME CREDITS



THE 2nd GCC RHEUMATOLOGY CONFERENCE

February 3-5, 2022 | Virtual Meeting



PRESIDENT'S WELCOME LETTER

Dear Valued Delegates

It is our great pleasure to invite you to the upcoming 2nd GCC Rheumatology Conference scheduled on 3rd-5th of February 2022. We have been eager to welcome you physically to Muscat during the best time of the year, weather-wise.

However, because of COVID-19 pandemic and recent imposed restrictions, it will be a completely virtual event to ensure maximum participation with the broadest audience. We reassure that the contents and quality of the event will not be negatively affected. A state of the art platform that can handle three thousand delegates is made available to broadcast the event.

The GCC rheumatology conference is an initiative created by all the sixth rheumatology societies or associations of the GCC countries. The first GCC rheumatology conference was held in Kuwait in 2019. It was hugely successful. It is a biannual event. The second GCC rheumatology was scheduled for 2021 but delayed due to COVID-19 pandemic.

The Oman Society of Rheumatology took the responsibility of conducting the second GCC rheumatology conference in Muscat. With dedication from our side and your strong support and commitment, together we can hold highly successful event. The OSR vision is aspiring toward detection, management, supporting research, advancement in knowledge, and education of rheumatic diseases in our region.

The GCC rheumatology societies' mission is to promote excellence in the management of patients with rheumatic diseases and to support health professionals and trainees; to help rheumatologists raise their standards at all healthcare levels and support access to clinical guidance, and providing the necessary information for better rheumatology care; to encourage and support medical trainees in pursuing rheumatology as a future career; to boost scientific and clinical knowledge exchange among the society members and across the GCC countries.

The scientific committee has prepared an enriching and fully comprehensive program that will be of added value to the attendees. The program will cover parallel keynote sessions for three consecutive days addressing adult and paediatric rheumatology topics. In addition to the diverse educational sessions presented by prominent Arab and International guest speakers, this congress will offer a platform to showcase various researches led by many Arab rheumatology teams through oral and poster presentations.

The society recognizes that health care progress depends heavily on a solid partnership between the pharmaceutical industry and health care providers. We sincerely thank our sponsors for their generous support in making this event possible.

We encourage a pan Arab participation and not just GCC to enhance and exchange ideas and knowledge. We have dedicated teams of executives from infomed who will facilitate and give you all the needed support to make sure that your participation and contributions are worthy and rewarding.

With my warmest wishes and high anticipation.

Dr. Ali Al Shirawi

OSR President,

Chairman of second GCC RHEUMATOLOGY CONFERENCE.



XELJANZ[®]
(tofacitinib citrate)

TOGETHER WE HAVE TREATED
>362,000
PATIENTS WITH XELJANZ[®]

Xeljanz is now
approved
in ⁶_____

R/A PsA UC psoriasis

1. **Abstract**
 2. **Introduction**
 3. **Methods**
 4. **Results**
 5. **Discussion**
 6. **Conclusion**
 7. **References**
 8. **Appendix**
 9. **Supplementary Material**
 10. **Tables**
 11. **Figures**
 12. **Tables**
 13. **Figures**
 14. **Tables**
 15. **Figures**
 16. **Tables**
 17. **Figures**
 18. **Tables**
 19. **Figures**
 20. **Tables**
 21. **Figures**
 22. **Tables**
 23. **Figures**
 24. **Tables**
 25. **Figures**
 26. **Tables**
 27. **Figures**
 28. **Tables**
 29. **Figures**
 30. **Tables**
 31. **Figures**
 32. **Tables**
 33. **Figures**
 34. **Tables**
 35. **Figures**
 36. **Tables**
 37. **Figures**
 38. **Tables**
 39. **Figures**
 40. **Tables**
 41. **Figures**
 42. **Tables**
 43. **Figures**
 44. **Tables**
 45. **Figures**
 46. **Tables**
 47. **Figures**
 48. **Tables**
 49. **Figures**
 50. **Tables**
 51. **Figures**
 52. **Tables**
 53. **Figures**
 54. **Tables**
 55. **Figures**
 56. **Tables**
 57. **Figures**
 58. **Tables**
 59. **Figures**
 60. **Tables**
 61. **Figures**
 62. **Tables**
 63. **Figures**
 64. **Tables**
 65. **Figures**
 66. **Tables**
 67. **Figures**
 68. **Tables**
 69. **Figures**
 70. **Tables**
 71. **Figures**
 72. **Tables**
 73. **Figures**
 74. **Tables**
 75. **Figures**
 76. **Tables**
 77. **Figures**
 78. **Tables**
 79. **Figures**
 80. **Tables**
 81. **Figures**
 82. **Tables**
 83. **Figures**
 84. **Tables**
 85. **Figures**
 86. **Tables**
 87. **Figures**
 88. **Tables**
 89. **Figures**
 90. **Tables**
 91. **Figures**
 92. **Tables**
 93. **Figures**
 94. **Tables**
 95. **Figures**
 96. **Tables**
 97. **Figures**
 98. **Tables**
 99. **Figures**
 100. **Tables**
 101. **Figures**
 102. **Tables**
 103. **Figures**
 104. **Tables**
 105. **Figures**
 106. **Tables**
 107. **Figures**
 108. **Tables**
 109. **Figures**
 110. **Tables**
 111. **Figures**
 112. **Tables**
 113. **Figures**
 114. **Tables**
 115. **Figures**
 116. **Tables**
 117. **Figures**
 118. **Tables**
 119. **Figures**
 120. **Tables**
 121. **Figures**
 122. **Tables**
 123. **Figures**
 124. **Tables**
 125. **Figures**
 126. **Tables**
 127. **Figures**
 128. **Tables**
 129. **Figures**
 130. **Tables**
 131. **Figures**
 132. **Tables**
 133. **Figures**
 134. **Tables**
 135. **Figures**
 136. **Tables**
 137. **Figures**
 138. **Tables**
 139. **Figures**
 140. **Tables**
 141. **Figures**
 142. **Tables**
 143. **Figures**
 144. **Tables**
 145. **Figures**
 146. **Tables**
 147. **Figures**
 148. **Tables**
 149. **Figures**
 150. **Tables**
 151. **Figures**
 152. **Tables**
 153. **Figures**
 154. **Tables**
 155. **Figures**
 156. **Tables**
 157. **Figures**
 158. **Tables**
 159. **Figures**
 160. **Tables**
 161. **Figures**
 162. **Tables**
 163. **Figures**
 164. **Tables**
 165. **Figures**
 166. **Tables**
 167. **Figures**
 168. **Tables**
 169. **Figures**
 170. **Tables**
 171. **Figures**
 172. **Tables**
 173. **Figures**
 174. **Tables**
 175. **Figures**
 176. **Tables**
 177. **Figures**
 178. **Tables**
 179. **Figures**
 180. **Tables**
 181. **Figures**
 182. **Tables**
 183. **Figures**
 184. **Tables**
 185. **Figures**
 186. **Tables**
 187. **Figures**
 188. **Tables**
 189. **Figures**
 190. **Tables**
 191. **Figures**
 192. **Tables**
 193. **Figures**
 194. **Tables**
 195. **Figures**
 196. **Tables**
 197. **Figures**
 198. **Tables**
 199. **Figures**
 200. **Tables**
 201. **Figures**
 202. **Tables**
 203. **Figures**
 204. **Tables**
 205. **Figures**
 206. **Tables**
 207. **Figures**
 208. **Tables**
 209. **Figures**
 210. **Tables**
 211. **Figures**
 212. **Tables**
 213. **Figures**
 214. **Tables**
 215. **Figures**
 216. **Tables**
 217. **Figures**
 218. **Tables**
 219. **Figures**
 220. **Tables**
 221. **Figures**
 222. **Tables**
 223. **Figures**
 224. **Tables**
 225. **Figures**
 226. **Tables**
 227. **Figures**
 228. **Tables**
 229. **Figures**
 230. **Tables**
 231. **Figures**
 232. **Tables**
 233. **Figures**
 234. **Tables**
 235. **Figures**
 236. **Tables**
 237. **Figures**
 238. **Tables**
 239. **Figures**
 240. **Tables**
 241. **Figures**
 242. **Tables**
 243. **Figures**
 244. **Tables**
 245. **Figures**
 246. **Tables**
 247. **Figures**
 248. **Tables**
 249. **Figures**
 250. **Tables**
 251. **Figures**
 252. **Tables**
 253. **Figures**
 254. **Tables**
 255. **Figures</**

FOR A LIFE THAT'S NON-STOP

COMPLETE SKIN CLEARANCE

Fast² and sustained complete clearance proven for 2 years in PsA¹

- 45% of TREMFYA® PsA patients achieved PASI 100 by Week 24²
- The majority of TREMFYA® PsA patients were completely or almost completely clear at 1 year³
- The majority of PsA patients achieved complete or almost complete skin clearance at 2 years^{4,5}



UNQUESTIONABLE JOINT EFFICACY

Sustained joint symptom relief proven for 2 years in PsA¹

- More than 6 out of 10 bio-naïve PsA patients achieved ACR20 response at Week 24²
- ACR20 response rates at 1 year maintained at 2 years and numerically increased for ACR50 and ACR70^{4,5}
- Limited structural damage progression, with radiographic progression rates gradually declining over 2 years of treatment⁴


**Lasting,
consistent
relief¹**



PROVEN DURABILITY

Most patients who started on TREMFYA®, stayed on TREMFYA® long-term⁴

- High levels of patient retention with TREMFYA® - 88% of TREMFYA® PsA patients still on treatment after 2 years⁴
- No labelled warnings or precautions for malignancy, IBD or depression^{1,2}
- 2% of PsA patients discontinued TREMFYA® due to an AE in 600 patient-years of follow-up²



¹84% of TREMFYA® q8w patients achieved ACR20 at Week 24 in DISCOVER-2²

²DISCOVER-2: In patients treated with TREMFYA® q8w, 74.8% of TREMFYA® q8w patients achieved ACR20 at 1 year, and 74% of TREMFYA® q8w patients achieved ACR20 at 2 years (non-responder imputation). In patients treated with TREMFYA® q8w, 46.4% of TREMFYA® q8w patients achieved ACR50 at 1 year, and 55% of TREMFYA® q8w patients achieved ACR50 at 2 years (non-responder imputation).^{2,4}

³48% of PsA patients treated with TREMFYA® achieved PASI 100 at Week 24 (n=47/8)³

⁴In DISCOVER-2: Patients randomized to TREMFYA® q8w at baseline. Patients achieving PASI 90 at Week 52: 74.4% (N=16). Patients achieving PASI 100 at Week 52: 52.8% (N=11).

⁵In DISCOVER-2: Patients randomized to TREMFYA® q8w at baseline. Patients achieving PASI 90 at Week 100: 70% (N=16). Patients achieving PASI 100 at Week 100: 53% (N=11).

⁶In patients randomized to TREMFYA® at baseline, and patients who crossed over from placebo at Week 24 (PsA), 88% of patients completed TREMFYA® through Week 100 in DISCOVER-2.

⁷When prescribing TREMFYA® q8w for psoriasis, it is recommended to evaluate liver enzymes at baseline and thereafter according to routine patient management. Very common adverse events of TREMFYA® were respiratory tract infections. Common adverse events of TREMFYA® were sinusitis or nasal, headache, diarrhea, arthralgia and injection site reactions.¹

⁸Durability, also known as patient retention or drug survival is a combination of efficacy, safety, tolerability and patient satisfaction or preference.⁴

⁹DISCOVER-2 was a Phase 3, double-blind, multi-centre, placebo-controlled study that evaluated the efficacy and safety of TREMFYA® in bio-naïve patients with active PsA.

References

1. Mohnselt B, et al. Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p50-Subunit of Interleukin-23, Through 2 Years: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologics-naïve Patients with Active Psoriatic Arthritis. Presented at the 2020 American College of Rheumatology Conference, March 18-20, 2021. Online. 2. Nason P, et al. Lancet 2020;395:1125-1136. 3. Mohnselt B, et al. Arthritis Rheumatol 2021;73:604-616.
4. TREMFYA® Summary of Product Characteristics, January 2021. 5. Gohlke R, et al. Rheumatology 2020;49:406-410.



THE 2nd GCC RHEUMATOLOGY CONFERENCE

February 3-5, 2022 | Virtual Meeting



GCC RHEUMATOLOGY PRESIDENT OF ASSOCIATIONS

President of the Oman Society of Rheumatology (OSR)

Dr. Ali Al Shirawi

President of the Kuwait Association for Rheumatology (KAR)

Dr. Fatemah Abu Tiban

President of the Qatar Rheumatology Society (QRS)

Dr. Samar Al Emadi

President of the Saudi Society for Rheumatology (SSR)

Dr. Hanan Al-Rayes

President of the Emirates Society of Rheumatology (ESR)

Dr. Jamal Al Saleh

President of the Bahrain Society of Rheumatology (BSR)

Dr. Saadeya Naji

ORGANIZING COMMITTEE

President of Conference of the 2nd GCC Rheumatology Conference

Dr. Ali Shirawi

Vice President, Chair in lead of Adult Rheumatology Program

Dr. Tariq Al Fanna Al Arai

President of Pediatric Rheumatology program

Dr. Reem Al Abdawani

Members

Dr. Talal Al Lawati

Dr. Ahmad Al Maqbali

SCIENTIFIC COMMITTEE

Chairman

Dr. Tariq Al Fanna Al Arai

Members

Dr. Batool Hassan Al Lawati

Dr. Farida Al-Balushi

Dr. Humaid Al Wahshi

Dr. Juma Alkaabi

Dr. Musallam Al Mashani

Dr. Nasra Al Adhoubi

PERSISTENCE ON TREATMENT SIMPONI®

WHY? SIMPONI®



Among patients with RA, and AS, SIMPONI® demonstrated high persistence rates at 5 years.¹⁻³

Approximately 70% of persistence rates across all indications

DEFINING PERSISTENCE OF TREATMENT²

Persistence is the duration of time from initiation to discontinuation of therapy.²

Adherence²

Efficacy³⁻⁵

Safety^{3,4}


Excellent Patient Experience³

PERSISTENCE
ON TREATMENT
RELIES ON:²⁻⁵



SIMPONI® DEMONSTRATED HIGH PERSISTENCE RATES IN DIFFERENT CATEGORIES OF PATIENTS⁶⁻⁷

Persistence rates in SIMPONI®-treated patients at 5 years across all indications



~70%

persistence rates across all indications⁶⁻⁷

TNF: Tumor Necrosis Factor; RA: Rheumatoid Arthritis; AS: Ankylosing Spondylitis; ADA: Adalimumab; ETA: Etanercept; CZP: Certolizumab Pegol; GLM: Golimumab.

REFERENCES:

- Rosini, M., Viapiana, O., Orsini, G., Fracassi, E., Idolazzi, L., Gatti, D., Adami, S. and Govoni, M. (2014). Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis? *Rheumatism*, 66(4), pp.285-303.
- Maniadas, N., Toth, E., Schiff, M., Wang, X., Nassim, M., Szegvari, B., Mourtin, L. and Curtis, J. (2016). A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences. *Advances in Therapy*, 35(9), pp.1333-1355.
- Bolge, S., Goren, A. and Tandon, N. (2015). Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective. *Patient Preference and Adherence*, 9, pp.121-131.
- Markenson, J., Gibofsky, A., Palmer, W., Keystone, E., Schiff, M., Feng, J. and Baumgartner, S. (2011). Persistence with Anti-Tumor Necrosis Factor Therapies in Patients with Rheumatoid Arthritis: Observations from the RADIUS Registry. *The Journal of Rheumatology*, 38(7), pp.1273-1281.
- Cramer, J., Roy, A., Burrell, A., Fairchild, C., Faldut, M., Ollendorf, D. and Wong, P. (2008). Medication Compliance and Persistence: Terminology and Definitions. *Value in Health*, 11(1), pp.44-47.
- Keystone, E., Genovese, M., Hall, S., Bae, S., Han, C., Gathany, T., Xu, S., Zhou, Y., Leu, J. and Hsia, E. (2015). Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial. *The Journal of Rheumatology*, 43(2), pp.298-306.
- Braun, J., Deodhar, A., Inman, R., van der Heide, D., Mack, M., Xu, S. and Hsu, B. (2011). Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. *Annals of the Rheumatic Diseases*, 71(5), pp.661-667.

CP-167366





RINVOQ®

upadacitinib

Our story in

NUMB³RS

Now approved in ³ rheumatology indications

RA **PsA** **AS**

Rheumatoid arthritis

Psoriatic arthritis

Ankylosing spondylitis

AbbVie Biopharmaceuticals GmbH
Suite 2901, U-Bora Tower
POBox: 118052
Business Bay, Dubai, UAE
OFFICE: +971 4 5506100
FAX: +971 4 5506101

For reporting Adverse Events, please contact:
Hotline: +971 56 413 5746
Email: PV.MEA@AbbVie.com

abbvie



THE 2nd GCC RHEUMATOLOGY CONFERENCE

February 3-5, 2022 | Virtual Meeting



DAY I | THURSDAY 3rd OF FEBRUARY 2022

Timing in UTC+4

🕒	ROOM I - MUSCAT	ROOM II - SALALAH
15:00 - 16:00	WORKSHOP I: How to Create a Registry? Dr. Adeeba Al-Herz (Kuwait)	WORKSHOP II: How to Conduct a Clinical Audit in Rheumatology ? HE Dr. Ahmed Al Mandhari (Oman)
16:00 - 17:00	WORKSHOP III: Rheumatology Mentorship in Academia: Guidance for Early Career Rheumatologists and Residency Trainees Dr. Yousef Al Weshahi (Oman)	WORKSHOP IV: A Practical Approach to Interpreting Autoimmune Labs: Pitfalls and Pearls Dr. Jalila Al-Shekaili (Oman)
17:00 - 18:00	Pediatric Symposium The Role of IL-1 in Autoinflammatory: from Monogenic Autoinflammatory Diseases to Hyperinflammation Dr. Marco Gattorno (Italy) Symposium Sponsored by Sobi	
Moderators	Dr. Farida Al Balushi (Oman)	
18:00 - 18:45	IL17i Role in the Management of Psoriatic Disease Dr. Adeeba Al-Herz (Kuwait) Symposium Sponsored by Novartis	
18:45 - 19:00	Break	
19:00 - 20:00	OPENING CEREMONY	
🕒	ROOM I - MUSCAT ADULT RHEUMATOLOGY	
20:00 - 21:15	PATIENTS ADVOCACY GROUPS IN THE GCC	
Moderators	Dr. Hussein Halabi (KSA) - Dr. Nasra Al Adhoubi (Oman)	
20:00 - 20:20	AAAA Group Dr. Lina El Kibbi (KSA) - Dr. Hussein Halabi (KSA)	
20:20 - 20:35	Saudi Society for Rheumatology Dr. Hanan Al-Rayes (KSA)	
20:35 - 20:50	Lupus Oman Ms. Mazzan Abdullah Al Farsi (Oman)	
20:50 - 21:05	Kuwait Lupus Group Dr. Shaimaa Al Asfour (Kuwait)	
21:05 - 21:15	Q & A	



THE 2nd GCC RHEUMATOLOGY CONFERENCE

February 3-5, 2022 | Virtual Meeting



DAY II | FRIDAY 4th OF FEBRUARY 2022

Timing in UTC+4

	ROOM I - MUSCAT ADULT RHEUMATOLOGY	
Moderator	Dr. Rajaie Namas (UAE)	
09:15 - 10:00	JAK Selectivity Impact on Management Dr. Farida Al Balushi (Oman)	Symposium Sponsored by AbbVie
10:00 - 10:10	WELCOME AND OPENING REMARKS Dr. Tariq Al Fanna Al Araqimi (Oman), Dr. Ali Al Shirawi (Oman)	
10:10 - 11:35	SESSION I: RHEUMATOID ARTHRITIS	
Moderator	Dr. Musallam Al Mashani (Oman)	
10:10 - 10:35	I - Cardiovascular Aspects of Rheumatoid Arthritis Dr. Suad Hannawi (UAE)	
10:35 - 10:50	The Saudi Guideline for Management of Rheumatoid Arthritis Dr. Hanan Al-Rayes (KSA)	
10:50 - 10:55	Q & A	
Moderators	Dr. Musallam Al Mashani (Oman), Prof. Adel Alawadhi (Kuwait)	
10:55 - 11:25	II- Rheumatoid Arthritis Research Session	
10:55 - 11:05	Abstract, Relationship Between Serum Level of Homocysteine, Leptin and Neopterin and Disease Activity in Rheumatoid Arthritis Patients with or without Extra-articular Manifestations Dr. Yasser A.Elmotaleb Gazar (KSA)	
11:05 - 11:15	Abstract, Tofacitinib in Patients with Rheumatoid Arthritis: Real World Data Dr. Zainab Kallow (Oman)	
11:15 - 11:25	Abstract, A Long-run Relationship Assessment of Air Pollutants on RA Disease Activity Score (DAS28): Evidence from the VECM Approach Dr. Ahmad Alsaber (Kuwait)	
11:25 - 11:35	Q & A	
11:35 - 11:50	Break	
11:50 - 12:35	A Mark of Experience Review of Clinical Trials for Xeljanz and Local Registry for Rheumatology Dr. Adeeba Al-Herz (Kuwait)	
	Symposium Sponsored by Pfizer	
12:35 - 13:30	Prayer and Lunch Break	



THE 2nd GCC RHEUMATOLOGY CONFERENCE

February 3-5, 2022 | Virtual Meeting



DAY II | FRIDAY 4th OF FEBRUARY 2022

Timing in UTC+4

🕒	ROOM I - MUSCAT ADULT RHEUMATOLOGY	
13:30 - 14:15	Discover New Era in PSA Management Dr. Felipe Julio Ramirez Garcia (Spain)	Symposium Sponsored by Janssen
Moderator	Dr. Farida Al Balushi (Oman)	
14:15 - 15:00	Enbrel's Place in the SPA Landscape Dr. Khalid Al Naqbi (UAE)	Symposium Sponsored by Pfizer
15:00 - 16:15	SESSION II: ANKYLOSING SPONDYLITIS & PSORIATIC ARTHRITIS	
Moderator	Dr. Eman Haji Hasan (Kuwait)	
15:00 - 15:30	I - Spondyloarthritis in the Gulf, Current and Future Vision Dr. Khalid Al Naqbi (UAE)	
15:30 - 15:35	Q & A	
Moderators	Dr. Aqeel Ghanem (Kuwait), Dr. Eman Haji Hasan (Kuwait)	
15:35 - 16:15	II- SPA (Ankylosing Spondylitis & Psoriatic Arthritis) Research Session	
15:35 - 15:45	Abstract, Applying the Arabic Version of CQR on Axial Spondyloarthritis Patients in Two Centers in Saudi Arabia Dr. Mariam Meshikhes (KSA)	
15:45 - 15:55	Abstract, Consensus-based Recommendations for the Management of Axial Spondyloarthritis Patients in the Kingdom of Saudi Arabia Dr. Mohammad Bedawi (KSA)	
15:55 - 16:05	Abstract, Association of Interleukin-6 (IL6), Interleukin-13 (IL-13) and Tumor Necrosis Factor-alpha (TNF-alpha) Gene Polymorphisms with Psoriatic Arthritis Susceptibility in Kuwaiti Patients Prof. Adel Alawadhi (Kuwait)	
16:05 - 16:15	Q & A	
16:15 - 16:30	Break	
16:30 - 17:15	A Clinical Perspective on Axial SpA Dr. Khalid Al Naqbi (UAE)	Symposium Sponsored by Novartis
17:15 - 18:40	SESSION III: RHEUMATOLOGY MEDICAL EDUCATION & POSTGRADUATE TRAINING	
Moderator	Dr. Tariq Al Fanna Al Araimi (Oman)	
17:15 - 17:40	I- Keynote Lecture: Current and Future Trends of Rheumatology Medical Education Prof. Dame Jane Dacre (UK)	
17:40 - 17:45	Q & A	



THE 2nd GCC RHEUMATOLOGY CONFERENCE

February 3-5, 2022 | Virtual Meeting



DAY II | FRIDAY 4th OF FEBRUARY 2022

Timing in UTC+4

	ROOM I - MUSCAT ADULT RHEUMATOLOGY	
Moderators	Prof. Dame Jane Dacre (UK), Dr. Tariq Al Fanna Al Araiimi (Oman)	
17:45 - 18:40	II- Rheumatology Postgraduate Fellowship Training Experiences in the GCC	
17:45 - 18:00	Rheumatology Postgraduate Fellowship Training Experiences in the GCC, Qatar Chapter Dr. Samar Al Emadi (Qatar)	
18:00 - 18:15	Rheumatology Postgraduate Fellowship Training Experiences in the GCC, Saudi Chapter Dr. Ali Al Rehaily (KSA)	
18:15 - 18:30	Rheumatology Postgraduate Fellowship Training Experiences in the GCC, UAE Chapter Dr. Khulood Khawaja (UAE)	
18:30 - 18:40	Q & A	
18:40 - 18:55	Break	
18:55 - 19:55	SESSION IV: CHALLENGING CASES IN ADULT RHEUMATOLOGY GCC	
Moderators	Dr. Saadeya Naji (Bahrain), Dr. Batool Hassan Al Lawati (Oman), Dr. Ahmed Zayat (UAE)	
18:55 - 19:05	Challenging Case in Vasculitis (KSA) Dr. Sadeem Alfraih (KSA)	
19:05 - 19:15	Challenging Case in Inflammatory Arthritis (Bahrain) Dr. Fajer Al Tamimi (Bahrain)	
19:15 - 19:25	Challenging Case in Systemic Sclerosis (UAE) Dr. Rajaie Namas (UAE)	
19:25 - 19:35	Challenging Case in Myositis (Kuwait) Dr. Amjad Alkadi (Kuwait)	
19:35 - 19:45	Challenging Case in Lupus (Qatar) Dr. Yousef Atiea Al Rimawi (Qatar)	
19:45 - 19:55	Q & A	
19:55 - 20:40	Reimagining the Standard of Care in PsA Dr. Ahmed Zayat (UAE)	Symposium Sponsored by Novartis



THE 2nd GCC RHEUMATOLOGY CONFERENCE

February 3-5, 2022 | Virtual Meeting



DAY II | FRIDAY 4th OF FEBRUARY 2022

Timing in UTC+4

🕒	ROOM II - SALALAH PEDIATRIC RHEUMATOLOGY
10:00 - 10:10	WELCOME AND OPENING REMARKS Dr. Reem Abdwani (Oman)
10:10 - 11:30	SESSION I: cSLE & AID
Moderator	Dr. Reem Abdwani (Oman), Dr. Muna Al Mutairi (Kuwait)
10:10 - 10:30	I- Monogenic Lupus Prof. Sulaiman Al-Mayouf (KSA)
10:30 - 10:40	Abstract, The Performance of the EULAR/ACR 2019 Classification Criteria for Monogenic Lupus Dr. Lujayn Akbar (KSA)
10:40 - 10:50	Abstract, Genetic Variants and Phenotypic Features of Childhood Large Vessel Vasculitis and Vasculitis-like Dr. Shahad Alansari (KSA)
10:50 - 11:10	II- Immune Dysregulation Dr. Buthaina Al Adba (Qatar)
11:10 - 11:20	Abstract, Scope of Managements of Saudi Patients with Interleukin-36 Receptor Antagonist Deficiency (DITRA): Case Series from a Tertiary Care Hospital Dr. Jude Al Masoud (KSA)
11:20 - 11:30	Q & A
11:30 - 11:45	Break
11:45 - 14:20	SESSION II: TRANSITION & JIA
Moderator	Prof. Sulaiman Al-Mayouf (KSA), Dr. Safiya Al Arawi (Oman)
11:45 - 12:05	I- Transition of Care Dr. Reem Abdwani (Oman)
12:05 - 12:15	Abstract, Transition Readiness in Adolescents and Young Adults with Chronic Rheumatic Disease in Oman: Today's Needs and Future Challenges Dr. Alrumitha Adil Alsabri (Oman)
12:15 - 12:35	II- TMJ Arthritis Dr. Banan Saud Al Rewaithi (KSA)
12:35 - 13:30	Prayer and Lunch Break



THE 2nd GCC RHEUMATOLOGY CONFERENCE

February 3-5, 2022 | Virtual Meeting



DAY II | FRIDAY 4th OF FEBRUARY 2022

Timing in UTC+4

🕒	ROOM II - SALALAH PEDIATRIC RHEUMATOLOGY
13:30 - 13:40	Abstract, Temporomandibular Joint Involvement in Children with Juvenile Idiopathic Arthritis Dr. Jubran Al Qanatish (KSA)
13:40 - 13:50	Abstract, Demographic Similarity and Variability Between Patients with Juvenile Idiopathic Arthritis in the Gulf Cooperation Council Countries Dr. Fatimah Al-Khars (KSA)
13:50 - 14:00	Abstract, Validation of "Red Flags" Index for Early Referral of Children with Features Suggestive of Juvenile Idiopathic Arthritis Dr. Bashayer AlAnazi (KSA)
14:00 - 14:10	Abstract, Juvenile Idiopathic Arthritis Diagnostic Delay, Treatment and Remission Rate in a Single Center in Abu Dhabi Dr. Khulood Khawaja (UAE)
14:10 - 14:20	Q & A
Moderator	Dr. Reem Abdwani (Oman)
14:20 - 15:05	Workshop V: Autoinflammatory Disorders in Children Dr. Marco Gattorno (Italy)
15:05 - 15:20	Break
15:20 - 17:00	SESSION III: MIS-C & MYOSITIS
Moderator	Dr. Buthaina Al Adba (Qatar), Dr. Khulood Khawaja (UAE)
15:20 - 15:40	I- Genetic Analysis in Children with MIS-C Dr. Muna Al Mutairi (Kuwait)
15:40 - 15:50	II- Abstract, MIS-C Experience - Oman Dr. Hilal Al Hashami (Oman)
15:50 - 16:00	III- Abstract, Clinical Characteristics and Outcomes of MIS-C Dr. Jubran Al Qanatish (KSA)
16:00 - 16:10	IV- Abstract, Pattern of Clinical Manifestations and Outcome of MIS-C Dr. Banan Saud Al Rewaithi (KSA)



THE 2nd GCC RHEUMATOLOGY CONFERENCE

February 3-5, 2022 | Virtual Meeting



DAY II | FRIDAY 4th OF FEBRUARY 2022

Timing in UTC+4



ROOM II - SALALAH | PEDIATRIC RHEUMATOLOGY

16:10 - 16:30 **V- Kawasaki Disease Scoring System**
Dr. Zaid Alhinai (Oman)

16:30 - 16:50 **VI- Inflammatory Myositis**
Dr. Abdulrahman Al Rasheed (KSA)

16:50 - 17:00 Q & A

17:00 - 17:15 Break

17:15 - 18:20 SESSION IV: CHALLENGING CASES

Moderator Dr. Abdulrahman Al Rasheed (KSA), Dr. Safiya Al Abrawi (Oman)

17:15 - 17:25 Challenging Case: Sarcoidosis, UAE
Dr. Ali Al Sarhan (UAE)

17:25 - 17:35 Challenging Case: GBS Lupus, UAE
Dr. Elham Beshir (UAE)

17:35 - 17:45 Challenging Case: Immune Dysregulation
Dr. Nashat Al Sukaiti (Oman)

17:45 - 17:55 Challenging Case: Systemic Vasculitis
Dr. Mahadev Lohano (Oman)

17:55 - 18:05 Challenging Case: Early Onset Recurrent Ulcer; Thinking Outside the Box
Dr. Alhanouf Abdullah Alsaleem (KSA)

18:05 - 18:20 Q & A



THE 2nd GCC RHEUMATOLOGY CONFERENCE

February 3-5, 2022 | Virtual Meeting



DAY III | SATURDAY 5th OF FEBRUARY 2022

Timing in UTC+4



ROOM I - MUSCAT | ADULT RHEUMATOLOGY

10:00 - 11:10

SESSION I: SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME

Moderator

Dr. Humaid Al Wahshi (Oman)

10:00 - 10:25

I- Updates in the Best Clinical Practices in Managing Patients with CAPS: Where Are We?
Prof. Munther Khamashta (UAE)

10:25 - 10:30

Q & A

Moderators

Dr. Jamal Al Saleh (UAE), Dr. Humaid Al Wahshi (Oman)

10:30 - 11:10

II- Systemic Lupus Erythematosus Research Session

10:30 - 10:40

Abstract, A Multicenter Longitudinal Study of the Prevalence and Mortality Rate of Systemic Lupus Erythematosus Patients in Oman: Oman Lupus Study
Dr. Nasra Al Adhoubi (Oman)

10:40 - 10:50

Abstract, The Outcome of Rituximab Therapy in Patients with Systemic Lupus Erythematosus
Dr. Mufaddal Alaithan (KSA)

10:50 - 11:00

Abstract, Virtual vs Actual Clinical Assessment Effect on Systemic Lupus Erythematosus Disease During Pandemic of COVID-19
Dr. Hajer AlZuhair (KSA)

11:00 - 11:10

Q & A

11:10 - 11:25

Break

11:25 - 12:45

SESSION II: COVID-19 & RHEUMATIC DISEASES

Moderator

Dr. Yaser Ghadanfar (Kuwait)

11:25 - 11:50

I- COVID-19 & Rheumatic Diseases Updates
Dr. Ibrahim Al Maghlouth (KSA)

11:50 - 12:00

Q & A



THE 2nd GCC RHEUMATOLOGY CONFERENCE

February 3-5, 2022 | Virtual Meeting



DAY III | SATURDAY 5th OF FEBRUARY 2022

Timing in UTC+4



ROOM I - MUSCAT | ADULT RHEUMATOLOGY

Moderators

Dr. Fatemah Abu Tiban (Kuwait)
Dr. Nasra Al Adhoubi (Oman)
Dr. Yaser Ghadanfar (Kuwait)

12:00 - 12:40

II- COVID-19 & Rheumatic Diseases Research Session

12:00 - 12:10

Abstract, Point Prevalence of Coronavirus Disease 2019 in a Multiethnic Cohort of Patients with Autoimmune Rheumatic Diseases in Qatar
Dr Karima Becetti (Qatar)

12:10 - 12:25

Abstract, Rheumatologic Aspects of the COVID-19 Pandemic: A Practical Resource for Physicians in Kuwait and the Gulf Region as Recommended by the Kuwait Association of Rheumatology
Dr. Fatemah Baroun (Kuwait)

12:25 - 12:35

Abstract, Humoral Response to mRNA-based COVID-19 Vaccine in Patients With Autoimmune Rheumatic Disease Retrospective Comparative Study
Dr. Omar Alsaed (Qatar)

12:35 - 12:45

Q & A

12:45 - 13:00

Break

13:00 - 14:25

SESSION III: UPDATES IN VASCULITIS

Moderator

Dr. Juma Alkaabi (Oman)

13:00 - 13:25

I- Current Treatments and Updates in Management of ANCA Associated Vasculitis
Dr. Abdullah Al Mutlaq (KSA)

13:25 - 13:30

Q & A

13:30 - 13:45

Break



THE 2nd GCC RHEUMATOLOGY CONFERENCE

February 3-5, 2022 | Virtual Meeting



DAY III | SATURDAY 5th OF FEBRUARY 2022

Timing in UTC+4



ROOM I - MUSCAT | ADULT RHEUMATOLOGY

Moderators

Dr. Abdullah Al Mutlaq (KSA)
Dr. Juma Alkaabi (Oman)

13:45 - 14:25

II- Vasculitis Research Session

13:45 - 13:55

Abstract, The First Published GCA Case-serie in Bahrain, Diagnosis and Management
Dr. Fatima Haji (Bahrain)

13:55 - 14:05

Abstract, Evaluating Behcet's Disease Activity Pattern in the Context of Major Organ Involvement
Dr. Lama AlTamimi (KSA)

14:05 - 14:15

Abstract, Frequency, Nature and Predictors of Serositis in Adult Patients with Behcet's Disease
Dr. Saad Alshalawi (KSA)

14:15 - 14:25

Q & A

14:25 - 14:40

Break

14:40 - 15:45

SESSION IV: CONNECTIVE TISSUE DISEASE

Moderators

Dr. Mohammed Omair (KSA)

14:40 - 15:10

I- SSc Updates in SSc/ILD
Dr. Khuloud Saleh (Kuwait)

15:10 - 15:15

Q & A

Moderators

Dr. Mohammed Omair (KSA)
Dr. Rajaie Namas (UAE)

15:15 - 15:10

II- Connective Tissue Disease Research Session

15:15 - 15:25

Abstract, The Demographic Data of Patients with Systemic Sclerosis in Sultanate of Oman
Dr. Shadha Al Kindi (Oman)

15:25 - 15:35

Abstract, Anti-SRP Myopathy- A Disabling Myopathy and its Response to Rituximab
Dr. Raven Haan (UAE)

15:35 - 15:45

Q & A

“



THE 2nd GCC RHEUMATOLOGY CONFERENCE

February 3-5, 2022 | Virtual Meeting



”

DAY III | SATURDAY 5th OF FEBRUARY 2022

Timing in UTC+4



ROOM I - MUSCAT | ADULT RHEUMATOLOGY

15:45 - 16:30

SESSION V: RHEUMATIC DISEASES & PREGNANCY

Moderator

Dr. Humaid Al Wahshi (Oman)

15:45 - 16:10

Rheumatic Disease & Pregnancy
Dr. Samar Al Emadi (Qatar)

16:10 - 16:15

Q & A

16:15 - 16:30

Best Abstracts Awards
Dr. Tariq Al Fanna Al Araimi (Oman), Dr. Ali Al Shirawi (Oman)

16:30 - 16:45

CLOSING CEREMONY



THE 2nd GCC RHEUMATOLOGY CONFERENCE

February 3-5, 2022 | Virtual Meeting



**OMAN SOCIETY OF RHEUMATOLOGY
WOULD LIKE TO THANK THE BELOW COMPANIE
FOR THEIR GENEROUS CONTRIBUTION**

PLATINUM



GOLD



SILVER



CONTRIBUTORS



Organized by:
Infomed
INTERNATIONAL FOR EVENTS

LEBANON

4th Floor, Qubic Center
Daoud Ammoun Street
Horsh Tabet - Sin El Fil
P.O. Box: 90-361 Beirut
Tel: +961 1 510880/1/2/3
Mobile: +961 71 103123

UAE

DMCC Business Centre
Almas Tower
Jumeirah Lakes
Dubai, United Arab Emirates
Unit No: 3820
Mobile: +971 50 9110475

KUWAIT

Mezzanine floor,
Aliya Complex
Salem Al Mubarak St
Block 2, Salmiya - Kuwait
Tel: +965 6556 7669

